Biodrugs

Papers
(The H4-Index of Biodrugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry251
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond153
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery93
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design89
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor78
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome63
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making59
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis56
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis51
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy44
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic40
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart37
Acknowledgement to Referees36
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies35
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials33
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202233
CAR-T Cells and the Kidney: Insights from the WHO Safety Database32
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?32
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy31
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?31
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review30
Malaria Vaccines: Progress to Date29
Progress and Challenges in the Treatment of Fabry Disease29
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data29
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer25
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?25
0.017956972122192